DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Carcinoma of the Breast

Interventions: Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2007-10-11

Last Posted Date: 2024-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 406

Registration Number: NCT00542451

Locations: 🇺🇸
Case Western University, Cleveland, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 17 locations

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Phase 1

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Interleukin-2

First Posted Date: 2007-09-14

Last Posted Date: 2020-07-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00529035

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function

Completed

Conditions: Ovarian Cancer

First Posted Date: 2007-09-05

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00525460

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Papillary Serous Mullerian Tumor
Clear Cell Mullerian Tumor

Interventions: Drug: bevacizumab
Drug: paclitaxel
Drug: erlotinib
Drug: carboplatin

First Posted Date: 2007-08-23

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00520013

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: therapeutic autologous lymphocytes
Genetic: Use of an artificial antigen presenting cell (aAPC) to generate CTL
Drug: GM-CSF
Radiation: Irradiation of cutaneous tumor lesion

First Posted Date: 2007-08-08

Last Posted Date: 2013-03-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00512889

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Vandetanib
Drug: Cyclophosphamide
Drug: Methotrexate

First Posted Date: 2007-07-04

Last Posted Date: 2013-11-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00496665

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Campath in Chronic GVHD

Phase 1

Completed

Conditions: Chronic Graft-vs.-Host Disease

Interventions: Drug: Alemtuzumab (Campath)

First Posted Date: 2007-07-03

Last Posted Date: 2013-08-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00495755

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2007-06-18

Last Posted Date: 2017-03-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00487513

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

Phase 1

Completed

Conditions: Follicular Lymphoma

Interventions: Biological: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells

First Posted Date: 2007-06-18

Last Posted Date: 2024-08-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00487305

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: CCI-779
Drug: Bortezomib

First Posted Date: 2007-06-06

Last Posted Date: 2013-11-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT00483262

Locations: 🇺🇸
Washington University in Saint Louis, St. Louis, Missouri, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy